Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobio Pharmaceuticals Group Co (OTCPK:JBPHF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Jacobio Pharmaceuticals Group Co's Enterprise Value for the quarter that ended in Dec. 2025 was $612.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-18.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co EV-to-EBIT Related Terms
Jacobio Pharmaceuticals Group Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's EV-to-EBIT falls into.
Jacobio Pharmaceuticals Group Co's current Enterprise Value is $365.37 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-18.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co (JBPHF) has a EV-to-EBIT of -19.49 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #999999 out of 376 companies in the Biotechnology industry.
Is Jacobio Pharmaceuticals Group Co's EV-to-EBIT too high?
Jacobio Pharmaceuticals Group Co's current EV-to-EBIT is -19.49. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #999999 out of 376 companies for EV-to-EBIT. This places Jacobio Pharmaceuticals Group Co in the lower half of its industry. The industry median EV-to-EBIT is 12.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.95, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current EV-to-EBIT is -19.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co (JBPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.26, compared to a current price of $0.64 — trading 146.3% above its estimated fair value. The current EV-to-EBIT is -19.49. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 32/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current EV-to-EBIT is -19.49 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.64 is trading 146.3% above its estimated GF Value™ of $0.26.
GuruFocus considers Jacobio Pharmaceuticals Group Co to be Significantly Overvalued.
Key valuation signals for JBPHF:
EV-to-EBIT: -19.49
GF Value™: $0.26 vs. price of $0.64 (146.3% above fair value)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Business Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
32GF Score
Get the complete analysis for JBPHF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
